PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Cancer Research and Treatment10.4143/crt.2016.54620174941001-1011Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung CancerYoungjoo Lee, Ki Hyeong Lee, Geon Kook Lee, Soo-Hyun Lee, Kun Young Lim, Jungnam Joo, Yun Jung Go, Jin Soo Lee, Ji-Youn Hanhttp://www.e-crt.org/upload/pdf/crt-2016-546.pdf, http://www.e-crt.org/journal/view.php?doi=10.4143/crt.2016.546, http://www.e-crt.org/upload/pdf/crt-2016-546.pdf
Lung Cancer10.1016/j.lungcan.2020.07.0172020147209-213Afatinib in patients with advanced non-small cell lung cancer harboring HER2 mutations, previously treated with chemotherapy: A phase II trialYun Fan, Jianhua Chen, Chengzhi Zhou, Huijuan Wang, Yongqian Shu, Jacky Zhang, Hairui Hua, Dennis Chin-Lun Huang, Caicun Zhouhttps://api.elsevier.com/content/article/PII:S0169500220305390?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0169500220305390?httpAccept=text/plain
Lung Cancer10.1016/0169-5002(95)98935-41995123307Results of a clinical multicentric randomized phase II study of non-small cell lung cancer treated with vinorelbine-cisplatin versus vinorelbine alonehttps://api.elsevier.com/content/article/PII:0169500295989354?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:0169500295989354?httpAccept=text/plain
Yearbook of Oncology10.1016/j.yonc.2012.07.00720122012187-188Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer: A Phase III TrialA.S. Tsaohttps://api.elsevier.com/content/article/PII:S1040174112000620?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1040174112000620?httpAccept=text/plain
Lung Cancer10.1016/j.lungcan.2018.10.014201812641-47A phase II study of afatinib treatment for elderly patients with previously untreated advanced non-small-cell lung cancer harboring EGFR mutationsHisao Imai, Kyoichi Kaira, Kensuke Suzuki, Masaki Anzai, Takeshi Tsuda, Tamotsu Ishizuka, Tomohito Kuwako, Ichiro Naruse, Kenji Nemoto, Junji Uchino, Nobutoshi Morozumi, Shinichi Ishihara, Koichi Minato, Takeshi Hisadahttps://api.elsevier.com/content/article/PII:S0169500218305981?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0169500218305981?httpAccept=text/plain
Lung Cancer10.1016/s0169-5002(97)89552-91996161120Randomized study of NavelbineR and cisplatin versus vindesine and cisplatin versus NavelbineR alone in 612 patients with advanced non-small cell lung cancer (NSCLC)https://api.elsevier.com/content/article/PII:S0169500297895529?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0169500297895529?httpAccept=text/plain
Lung Cancer10.1016/0169-5002(93)90590-t199385-6348Mitomycin C plus vindesine or cisplatin plus epirubicin in previously treated patients with symptomatic advanced non-small-cell lung cancerhttps://api.elsevier.com/content/article/PII:016950029390590T?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:016950029390590T?httpAccept=text/plain
Reactions Weekly10.1007/s40278-017-37787-820171675119-19Afatinibhttp://link.springer.com/article/10.1007/s40278-017-37787-8/fulltext.html, http://link.springer.com/content/pdf/10.1007/s40278-017-37787-8.pdf, http://link.springer.com/content/pdf/10.1007/s40278-017-37787-8.pdf
Lung Cancer: Targets and Therapy10.2147/lctt.s16310201147Afatinib treatment in advanced non-small cell lung cancerLynn Campbell, Hurwitz, Scullinhttps://www.dovepress.com/getfile.php?fileID=11133
Reactions Weekly10.1007/s40278-017-31351-y20171656121-21Afatinibhttp://link.springer.com/content/pdf/10.1007/s40278-017-31351-y.pdf, http://link.springer.com/article/10.1007/s40278-017-31351-y/fulltext.html, http://link.springer.com/content/pdf/10.1007/s40278-017-31351-y.pdf